Changes in protein profiles of multiple myeloma cells in response to bortezomib

Turan T., Sanli-Mohamed G., Baran Y.

LEUKEMIA & LYMPHOMA, cilt.54, sa.5, ss.1061-1068, 2013 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 54 Sayı: 5
  • Basım Tarihi: 2013
  • Doi Numarası: 10.3109/10428194.2012.735668
  • Dergi Adı: LEUKEMIA & LYMPHOMA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Sayfa Sayıları: ss.1061-1068
  • Anahtar Kelimeler: Bortezomib, multiple myeloma, proteomics, MALDI-TOF-TOF, mass spectrometry, NF-KAPPA-B, PROTEASOME INHIBITOR PS-341, MOLECULAR-CLONING, INDUCED APOPTOSIS, TERMINAL KINASE, ACTIVATION, CANCER, PATHWAYS, TARGET, IDENTIFICATION
  • Gazi Üniversitesi Adresli: Evet

Özet

The objective of this study was to determine the changes in protein profiles of U-266 multiple myeloma cells in response to bortezomib. Bortezomib inhibited cell proliferation and increased the loss of mitochondrial membrane potential and caspase-3 activity in a dose-dependent manner. DECODON Delta2D Version 4.3 software demonstrated 37 differentially expressed protein spots: five proteins were newly formed, 10 proteins were lost, 12 proteins were up-regulated and 10 proteins were down-regulated in bortezomib-treated cells as compared to untreated cells. Some of the identified proteins after mass spectrometric analysis were as follows: apoptosis regulatory protein Siva (newly formed), caspase recruitment domain-containing protein 14 (lost), Ras-related protein Rab-25 (up-regulated), nuclear factor kappa B (NF-kappa B) p105 subunit (down-regulated). In summary, differentially expressed proteins of MM U-266 cells in response to bortezomib were analyzed and identified. The data obtained from this study may indicate the use of bortezomib for the treatment of various diseases.